ArticleInfection and immunity2004
In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Blocking Superantigen-Mediated Diseases: Challenges and Future Trends.Journal of immunology research · 2024Review
- Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival.Journal for immunotherapy of cancer · 2020Article
- Review
- Staphylococcal and Streptococcal Superantigens Trigger B7/CD28 Costimulatory Receptor Engagement to Hyperinduce Inflammatory Cytokines.Frontiers in immunology · 2019Article
- Article
- Models matter: the search for an effective Staphylococcus aureus vaccine.Nature reviews. Microbiology · 2014Review
- Bacterial Toxins-Staphylococcal Enterotoxin B.Microbiology spectrum · 2013Article
- Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions.Toxins · 2013Review
- Staphylococcal and streptococcal superantigen exotoxins.Clinical microbiology reviews · 2013Review
- PI3K/Akt/mTOR, a pathway less recognized for staphylococcal superantigen-induced toxicity.Toxins · 2012Review
- Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome.The FEBS journal · 2011Review
- Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.PLoS biology · 2011Article
- Human leukocyte antigen class II transgenic mouse model unmasks the significant extrahepatic pathology in toxic shock syndrome.The American journal of pathology · 2011Article
- Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock.The Journal of biological chemistry · 2011Article
- Interferon gamma-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome.PloS one · 2011Article
- Article
- Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock.Toxins · 2010Review
- Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies.Infection and immunity · 2010Article
- Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor.Physiological genomics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Superantigen peptide antagonists failed to block T-cell activation and cytokine production as well as toxic shock induced by staphylococcal enterotoxin B (SEB) in HLA class II transgenic mice. They also failed to inhibit the binding of SEB to HLA class II molecules as well as activation of human T lymphocytes in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.